Scripps Tumorgraft Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Scripps Translational Science Institute
Information provided by (Responsible Party):
Laura Goetz, M.D., Scripps Translational Science Institute Identifier:
First received: November 6, 2012
Last updated: January 6, 2014
Last verified: January 2014

Study the genetic traits of cancerous tissues and to help improve cancer treatment by developing tumor models for studying new cancer drugs.

Solid Tumor Malignancy or Hematologic Malignancy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Scripps Tumorgraft Study

Resource links provided by NLM:

Further study details as provided by Scripps Translational Science Institute:

Primary Outcome Measures:
  • Facilitate the development of individualized tumorgraft models for many different types of cancer. [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Blood and tissue samples

Estimated Enrollment: 100
Study Start Date: November 2012
Estimated Primary Completion Date: November 2022 (Final data collection date for primary outcome measure)
Cancer Diagnosis


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Adults with a solid tumor malignancy or a hematologic malignancy


Inclusion Criteria:

  • Age 21 or over
  • diagnosis of a solid tumor malignancy, either resectable or metastatic or a hematologic malignancy
  • cognitively and emotionally able to give informed consent

Exclusion Criteria:

  • Under age 21
  • Not cognitively or emotionally able to give informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01726699

Contact: Sharon Haaser, RN, BSN 858-554-5758

United States, California
Scripps Translational Science Institute Recruiting
La Jolla, California, United States, 92037
Contact: Sharon Haaser, RN, BSN    858-554-5758   
Sponsors and Collaborators
Scripps Translational Science Institute
Principal Investigator: Laura Goetz, MD Director, Applied Genetic Epidemiology
  More Information

No publications provided

Responsible Party: Laura Goetz, M.D., Director, Applied Genetic Epidemiology, Scripps Translational Science Institute Identifier: NCT01726699     History of Changes
Other Study ID Numbers: 12-6011
Study First Received: November 6, 2012
Last Updated: January 6, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Neoplasms processed this record on September 15, 2014